Under intense criticism, Gilead forsakes monopoly status for its experimental Covid-19 drug
Gilead Sciences has asked the FDA to rescind orphan drug designation for an experimental medicine being tested to combat #Covid-19.
In an unexpected move, Gilead Sciences (GILD) has asked the Food and Drug Administration to rescind orphan drug designation for an experimental medicine being tested to combat Covid-19. The request comes after intense criticism that it unfairly pursued a lucrative monopoly for remdesivir.
The designation, which offers a drug maker seven years of marketing exclusivity, drew immediate condemnation from consumer advocates because orphan status is reserved for medicines targeting rare diseases that afflict 200,000 or fewer people. The
